Antidepressant Prescribing Online: What Patterns Your Care Team Is Tracking

Getting an antidepressant prescription is the easy part. Getting the prescription to work, over the weeks and months that actually matter, requires something most care models do not provide: someone tracking what is happening between visits.

The clinical reality of antidepressant prescribing is that the drug is only one variable. Whether it works, at what dose, how quickly, and whether the patient stays on it long enough to find out, depends entirely on what gets monitored and when. A prescriber who sees you once every three months is making decisions based on a 15-minute snapshot of a 90-day experience they were not watching.

Online prescribing platforms have made it easier to start an antidepressant. What they have not uniformly done is build the monitoring structure that makes that prescription clinically sound over time. Here is what that structure should look like, and what your care team should be watching.

Who Is Actually Prescribing Your Antidepressant

Most people assume that antidepressants come from psychiatrists. Most of them do not. Research published in Frontiers in Psychiatry estimated that approximately 62% of antidepressant prescriptions in the U.S. are written by primary care physicians. The psychiatric workforce shortage, with its multi-month wait times and geographic gaps, has shifted most front-line prescribing to providers whose training and bandwidth for psychiatric monitoring are not optimized for the task.

This is not a criticism of primary care providers. They are filling a genuine gap in the system. It is a structural description of why antidepressant monitoring often falls short: the providers doing most of the prescribing have 15-minute appointment slots and full panels, with no systematic mechanism for between-visit contact on medication response.

A systematic review and meta-analysis of 35 studies found that approximately 49-50% of patients with major psychiatric disorders do not adhere to their prescribed psychotropic medication regimen. Among patients with major depressive disorder specifically, non-adherence rates are consistently close to 50%. The gap between what is prescribed and what is maintained is not primarily a patient problem. It is a monitoring structure problem.

The Five Patterns That Drive Good Prescribing

A care team that is doing its job is not simply watching for serious adverse events. It is tracking five patterns continuously, each of which provides clinically actionable information.

1. Symptom Trajectory

The central question in antidepressant prescribing is not "how are you feeling today?" It is "how does how you are feeling today compare to how you were feeling at week two, week four, and week six?" Trajectory is what matters. A patient who reports moderate symptoms at week six is in a different clinical situation if those symptoms have been declining steadily versus if they have been flat since week two.

The PHQ-9 is the most widely validated self-report instrument for measuring depression severity and tracking treatment response. A change in PHQ-9 score across time points, not a single cross-sectional score, is what allows a prescriber to determine whether the medication is producing the intended effect. This requires that the assessment happen at regular intervals, which in turn requires a monitoring structure that does not depend entirely on scheduled appointments.

2. Side Effect Emergence and Timing

SSRI side effects are most prominent in the first two to four weeks of treatment, before the therapeutic benefit has had time to develop. Nausea, sleep disruption, activation, and headaches are common in this window and in most cases transient. Research published in the Primary Care Companion to the Journal of Clinical Psychiatry documented that physicians systematically underestimate the rate of side effects in their patients, precisely because those side effects emerge between appointments, not during them.

A care team that is not in contact during weeks one through four is not tracking the period of maximum discontinuation risk. The patients who stop their antidepressant at week two because of nausea are not stopping because the drug failed. They are stopping because no one was there to explain that the nausea is transient and the benefit is still six weeks away.

3. Adherence Consistency

Antidepressants require daily consistent dosing to maintain therapeutic blood levels. Skipped doses, irregular timing, and dose reductions made without clinical guidance can all reduce or negate treatment response. A care team tracking adherence data, even informally through daily check-ins, can identify when inconsistency is emerging before it produces a clinical consequence.

4. Sleep Quality

Sleep and antidepressant response are bidirectionally linked. Poor sleep during treatment can blunt antidepressant response, and antidepressants themselves alter sleep architecture during the first weeks on the drug. Tracking sleep quality alongside mood gives the prescriber information that a PHQ-9 score alone does not capture: whether the sleep disruption is a side effect, a symptom, or a signal that the dose or timing needs adjustment.

5. The "I Feel Better" Risk Window

The most clinically dangerous moment in antidepressant treatment is not the side effect period. It is the improvement window. A 2021 randomized controlled trial in the New England Journal of Medicine found that patients who discontinued their antidepressants when they felt well had a 56% relapse rate within 52 weeks, compared to 39% for those who maintained therapy, with a hazard ratio of 2.06. A care team that is not in contact when the patient reaches the improvement window cannot prevent the misread that feeling better means treatment is complete.

Why Measurement-Based Care Changes Outcomes

Measurement-based care refers to the systematic use of validated clinical instruments, most commonly the PHQ-9 for depression and the GAD-7 for anxiety, at regular intervals to assess treatment response and guide clinical decisions. The APA and other major professional organizations recommend it as standard practice in psychiatric treatment. In practice, it is rarely implemented with the frequency that guidelines recommend.

The COMET trial demonstrated that regular patient symptom monitoring with feedback to physicians improved outcomes of depression treatment in the primary care setting. The mechanism is straightforward: prescribers who receive objective, time-stamped symptom data make better treatment decisions than those working from reconstructed verbal reports gathered at infrequent appointments.

The PHQ-9 does not replace clinical judgment. It gives that judgment something to work with. A prescriber reviewing a graph of PHQ-9 scores across 12 weeks of treatment is looking at something qualitatively different from a patient answering "how have you been feeling since your last visit?" Both are valuable. The first is traceable, objective, and actionable in ways the second is not.

The First Month: Where Most Prescriptions Fail

The window between starting an antidepressant and reaching the four-to-six-week mark for full therapeutic assessment is where most treatment failures occur. Research from the Mental Health Research Network found that approximately 30% of patients discontinue antidepressants within the first month, and up to 60% stop within three months.

The APA's practice guidelines for major depressive disorder recommend clinical follow-up within the first two to four weeks of a new antidepressant trial specifically because this is the highest-risk period. In standard outpatient practice, workforce constraints mean this recommendation is routinely unmet. The patient who starts sertraline on a Monday and develops nausea by Thursday has no clinical contact until their next scheduled appointment.

Between-visit contact during this window is not a luxury. It is the intervention that closes the gap between what the data shows about early discontinuation and what clinical care actually delivers. The prescriber who is available when side effects emerge in week two is making the difference between a patient who stays on treatment and one who stops before the medication has had a chance to work.

The Improvement Window and Its Risk

The counterintuitive reality of antidepressant treatment is that the moment of greatest clinical achievement, when symptoms improve and the patient feels meaningfully better, is also the moment of greatest discontinuation risk. The patient who stops their medication at month three because they feel better is not making an error of judgment. They are responding correctly to a genuine clinical signal without the context that would allow them to interpret it accurately.

Feeling better on an antidepressant does not mean the underlying neurobiological vulnerability has resolved. It means the medication is doing its job. The APA practice guidelines recommend maintaining antidepressant therapy for at least four to nine months after achieving remission following a first depressive episode, and longer for patients with a history of recurrent episodes.

The prescriber who can say, at the moment the patient reports improvement, "your PHQ-9 score just crossed into the remission range for the first time this week, and here is what stopping now typically produces," is delivering a different quality of care than one who hears "I feel better" at a quarterly appointment and nods along.

What Good Online Prescribing Actually Looks Like

Not every online prescribing platform provides the monitoring structure that good antidepressant prescribing requires. The key questions to ask:

• Is the initial intake clinically comprehensive? A platform that asks about your current symptoms and nothing else is not building the baseline from which trajectory can be assessed. Good intake captures your full history, prior medication trials, current medications, and treatment goals.
• Does a licensed prescriber review your intake and approve your treatment plan before anything is prescribed? If the answer is ambiguous or the platform cannot specify what the prescriber reviews, that is a significant gap.
• Is there a structured mechanism for between-visit contact during the first month? The highest-risk window for early discontinuation is weeks one through four. A platform that relies entirely on scheduled appointments cannot intervene during this window.
• Are validated instruments, like the PHQ-9, used at regular intervals? Measurement-based care requires systematic data collection. It cannot happen through verbal check-ins alone.
• What happens when improvement is reported? A platform that treats "I feel better" as the end of the clinical conversation is not tracking the most important risk window in antidepressant treatment.

How SiggyMD Monitors Antidepressant Treatment

SiggyMD's care model is built around the monitoring structure that good antidepressant prescribing requires. The AI intake captures a complete clinical picture: symptom history, prior medication experience, sleep quality, functional impairment, and treatment goals. That information goes to a licensed prescriber who reviews the full picture, including PHQ-9 results and specific clinical considerations, before approving any treatment plan.

After treatment begins, daily check-ins provide the between-visit data that the prescriber uses to monitor trajectory, catch side effects early, and identify when the improvement window has arrived, along with the clinical context to explain what it means. The prescriber is not working from memory or reconstruction at each follow-up. They have structured data on how the patient has tracked since treatment started.

"What antidepressant prescribing most often lacks is not good initial decision-making," says Daniel Montville, MD, of the SiggyMD clinical team. "It is the monitoring structure that keeps the decision-making updated as the patient's actual response unfolds. A prescription at day one and a follow-up at week twelve leaves an 83-day clinical blind spot. That blind spot is where most treatment failures happen."

What Members Are Saying

Member stories reflect real experiences. Names and identifying details have been changed to protect privacy. Results vary. SiggyMD is currently invite-only.

Frequently Asked Questions

What Patterns Do Prescribers Track When Managing Antidepressants?

Good antidepressant management tracks five core patterns over time: symptom trajectory using validated instruments like the PHQ-9, side effect emergence and its timing relative to clinical benefit, adherence consistency including dose timing and any missed doses, sleep quality (which is both a side effect indicator and a treatment response signal), and the "I feel better" risk window, the point at which improvement is misread as permission to stop. All five require between-visit data to track accurately, not just information gathered at scheduled appointments.

How Long Before a Prescriber Should Follow Up on a New Antidepressant?

The American Psychiatric Association's practice guidelines recommend follow-up within the first two to four weeks of a new antidepressant trial. This timing corresponds to the highest-risk window for early discontinuation, when side effects are most prominent and clinical benefit has not yet fully developed. In standard outpatient practice, workforce constraints mean this recommendation is frequently unmet. Between-visit monitoring through structured check-ins can extend clinical coverage during this window without requiring additional scheduled appointments.

Why Do So Many People Stop Antidepressants in the First Three Months?

Approximately 30% of patients stop their antidepressant within the first month, and up to 60% stop within three months, according to Mental Health Research Network data. The primary drivers are side effects in the acute phase before clinical benefit develops, the absence of monitoring that could address those side effects, and the common misread that early improvement means the medication is no longer needed. These are structural failures of the care model, not patient compliance failures.

What Is Measurement-Based Care in Psychiatry?

Measurement-based care refers to the systematic use of validated clinical instruments at regular intervals to assess treatment response and guide prescribing decisions. In psychiatric practice, this typically involves the PHQ-9 for depression and the GAD-7 for anxiety. The research evidence supports measurement-based care as improving treatment outcomes compared to clinical decisions based on verbal reports alone. It requires regular data collection, not just scheduled appointments, making between-visit monitoring central to implementation.

When Is It Safe to Stop Taking an Antidepressant?

The decision to stop an antidepressant should be made with a prescriber who can review your current symptom data, prior episode history, and the clinical timeline of your response. The APA recommends maintaining antidepressant therapy for at least four to nine months after achieving remission for a first depressive episode, and longer for patients with recurrent episodes. Stopping when you first feel better is clinically premature in the majority of cases. Any planned discontinuation should involve a supervised tapering schedule, not abrupt stopping, to minimize discontinuation syndrome risk.

Does Online Antidepressant Prescribing Include Monitoring?

It depends on the platform. Some online prescribing platforms provide comprehensive monitoring: structured intake reviewed by a licensed prescriber, validated symptom tracking, and a mechanism for clinical response between scheduled appointments. Others function closer to a prescription refill service, providing medication without the clinical monitoring that makes that medication safe and effective over time. The key questions to ask are whether a licensed prescriber reviews your full intake before approving your plan, and whether there is a structured mechanism for between-visit contact during the highest-risk period.

Bottom Line

Getting an antidepressant prescription is not the hard part. Maintaining it through the side effect window, calibrating it during the response assessment period, and sustaining it through the improvement window that should prompt continuation rather than stopping, requires a monitoring structure that most prescribing relationships do not currently provide.

The patterns your care team should be tracking are not complicated. They are a symptom trajectory, side effect timing, adherence consistency, sleep quality, and the context for what "I feel better" actually means clinically. What they require is contact at the right intervals, not just at scheduled appointments.

Online prescribing can provide that structure. Whether it does depends on whether the platform was designed around monitoring from the start, or whether it simply moved the prescription request to a screen.

Sources

1. Piacentino D, et al. Therapeutic Drug Monitoring of Antidepressants: An Underused but Potentially Valuable Tool in Primary Care. Frontiers in Psychiatry. 2022;13:867840.
2. Semahegn A, et al. Psychotropic medication non-adherence and its associated factors among patients with major psychiatric disorders: a systematic review and meta-analysis. Systematic Reviews. 2020;9(1):17.
3. Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: Validity of a brief depression severity measure. Journal of General Internal Medicine. 2001;16(9):606-613.
4. Ferguson JM. SSRI Antidepressant Medications: Adverse Effects and Tolerability. Prim Care Companion J Clin Psychiatry. 2001;3(1):22-27.
5. Lewis G, et al. Maintenance or Discontinuation of Antidepressants in Primary Care. New England Journal of Medicine. 2021;385:1257-1267.
6. Rossom RC, et al. Antidepressant adherence across diverse populations and healthcare settings. Depression and Anxiety. 2016;33(8):765-774.
7. Yeung A, et al. Clinical Outcomes in Measurement-Based Treatment (COMET): a trial of depression monitoring and feedback to primary care physicians. Depression and Anxiety. 2012;29(10):865-873.
8. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder. APA. Accessed May 2026.